Melanoma mRNA vaccine halves risk of recurrence, metastasis
A recent study reveals that an individualized mRNA vaccine for surgically resected melanoma, developed by Moderna and Merck, significantly reduces recurrence and distant spread risks over a five-year period. When combined with Keytruda, it boosts survival rates, showcasing the potential… Read More »Melanoma mRNA vaccine halves risk of recurrence, metastasis